A single-dose F1-based mRNA-LNP vaccine provides protection against the lethal plague bacterium.

Autor:	Kon E; Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.; Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel.; Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel.; Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel., Levy Y; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel., Elia U; Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.; Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel.; Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel.; Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel.; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel., Cohen H; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel., Hazan-Halevy I; Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.; Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel.; Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel.; Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel., Aftalion M; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel., Ezra A; Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.; Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel.; Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel.; Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel., Bar-Haim E; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel., Naidu GS; Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.; Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel.; Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel.; Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel., Diesendruck Y; Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.; Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel.; Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel.; Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel., Rotem S; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel., Ad-El N; Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.; Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel.; Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel.; Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel., Goldsmith M; Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.; Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel.; Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel.; Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel., Mamroud E; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel., Peer D; Laboratory of Precision NanoMedicine, Shmunis School for Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel.; Center for Nanoscience and Nanotechnology, Tel Aviv University, Tel Aviv 69978, Israel.; Department of Materials Sciences and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 69978, Israel.; Cancer Biology Research Center, Tel Aviv University, Tel Aviv 69978, Israel., Cohen O; Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness-Ziona 76100, Israel.
Jazyk:	angličtina
Zdroj:	Science advances [Sci Adv] 2023 Mar 10; Vol. 9 (10), pp. eadg1036. Date of Electronic Publication: 2023 Mar 08.
DOI:	10.1126/sciadv.adg1036
Abstrakt:	Messenger RNA (mRNA) lipid nanoparticle (LNP) vaccines have emerged as an effective vaccination strategy. Although currently applied toward viral pathogens, data concerning the platform's effectiveness against bacterial pathogens are limited. Here, we developed an effective mRNA-LNP vaccine against a lethal bacterial pathogen by optimizing mRNA payload guanine and cytosine content and antigen design. We designed a nucleoside-modified mRNA-LNP vaccine based on the bacterial F1 capsule antigen, a major protective component of Yersinia pestis , the etiological agent of plague. Plague is a rapidly deteriorating contagious disease that has killed millions of people during the history of humankind. Now, the disease is treated effectively with antibiotics; however, in the case of a multiple-antibiotic-resistant strain outbreak, alternative countermeasures are required. Our mRNA-LNP vaccine elicited humoral and cellular immunological responses in C57BL/6 mice and conferred rapid, full protection against lethal Y. pestis infection after a single dose. These data open avenues for urgently needed effective antibacterial vaccines.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu